Promising results after percutaneous mitral valve repair.

Danish medical bulletin Pub Date : 2011-07-01
Nikolaj Ihlemann, Olaf Franzen, Erik Jørgensen, Peter Bo Hansen, Christian Hassager, Jacob Eifer Møller, Lars Søndergaard
{"title":"Promising results after percutaneous mitral valve repair.","authors":"Nikolaj Ihlemann,&nbsp;Olaf Franzen,&nbsp;Erik Jørgensen,&nbsp;Peter Bo Hansen,&nbsp;Christian Hassager,&nbsp;Jacob Eifer Møller,&nbsp;Lars Søndergaard","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Mitral valve regurgitation (MR) is the secondmost frequent valve disease in Europe. Untreated MR causes considerable morbidity and mortality. In the elderly, as many as half of these patients are denied surgery because of an estimated high surgical risk. Percutaneous mitral valve repair with the MitraClip system resembles the Alfieristitch where a clip is used to connect the tip of the mitral valve leaflets.</p><p><strong>Material and methods: </strong>Sixteen patients with MR of various origins (functional/degenerative) were treated with the MitraClip system. All patients were highly symptomatic with dyspnoea (New York Heart Association (NYHA) grade three) and MR grade three or more, and had been turned down for surgery due to an excessively high risk.</p><p><strong>Results: </strong>MR was reduced in all but one patient, generally from grade 3.5±0.5 to grade 1.4±0.9. A total of four patients (25%) received two clips. Thirty-day complications were as follows: one patient died, one had a stroke (speech sequelae), one patient had a new chord rupture that was treated surgically. During 90 days of follow-up, symptoms of dyspnoea diminished (reduction of 1 NYHA grade) and the 6-minute walk test results improved from 171±99 to 339±134 metres (p<0.001).</p><p><strong>Conclusion: </strong>Percutaneous mitral valve repair with the MitraClip system is now available in Denmark. The treatment is a reasonable alternative in patients with MR and a high estimated surgery risk.</p><p><strong>Funding: </strong>Not relevant.</p><p><strong>Trial registration: </strong>Not relevant.</p>","PeriodicalId":11019,"journal":{"name":"Danish medical bulletin","volume":"58 7","pages":"A4299"},"PeriodicalIF":0.0000,"publicationDate":"2011-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Danish medical bulletin","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Mitral valve regurgitation (MR) is the secondmost frequent valve disease in Europe. Untreated MR causes considerable morbidity and mortality. In the elderly, as many as half of these patients are denied surgery because of an estimated high surgical risk. Percutaneous mitral valve repair with the MitraClip system resembles the Alfieristitch where a clip is used to connect the tip of the mitral valve leaflets.

Material and methods: Sixteen patients with MR of various origins (functional/degenerative) were treated with the MitraClip system. All patients were highly symptomatic with dyspnoea (New York Heart Association (NYHA) grade three) and MR grade three or more, and had been turned down for surgery due to an excessively high risk.

Results: MR was reduced in all but one patient, generally from grade 3.5±0.5 to grade 1.4±0.9. A total of four patients (25%) received two clips. Thirty-day complications were as follows: one patient died, one had a stroke (speech sequelae), one patient had a new chord rupture that was treated surgically. During 90 days of follow-up, symptoms of dyspnoea diminished (reduction of 1 NYHA grade) and the 6-minute walk test results improved from 171±99 to 339±134 metres (p<0.001).

Conclusion: Percutaneous mitral valve repair with the MitraClip system is now available in Denmark. The treatment is a reasonable alternative in patients with MR and a high estimated surgery risk.

Funding: Not relevant.

Trial registration: Not relevant.

经皮二尖瓣修复后的良好效果。
简介:二尖瓣反流(MR)是欧洲第二常见的瓣膜疾病。未经治疗的MR会导致相当高的发病率和死亡率。在老年人中,由于估计手术风险高,多达一半的患者被拒绝手术。使用MitraClip系统进行经皮二尖瓣修复,类似于alfieristich,其中使用夹子连接二尖瓣小叶的尖端。材料和方法:使用MitraClip系统治疗16例不同来源(功能性/退行性)的MR患者。所有患者均有严重的呼吸困难症状(纽约心脏协会(NYHA)三级)和MR三级或以上,并且由于风险过高而被拒绝手术。结果:除1例患者外,所有患者的MR均降低,一般从3.5±0.5级降至1.4±0.9级。共有4例患者(25%)接受了2个夹子。30天的并发症如下:1例死亡,1例中风(言语后遗症),1例手术治疗新弦破裂。在90天的随访中,呼吸困难症状减轻(NYHA等级降低1级),6分钟步行测试结果从171±99米改善到339±134米(结论:经皮MitraClip系统的二尖瓣修复现已在丹麦可用。对于核磁共振和高手术风险的患者,这种治疗是一种合理的选择。资金:无关紧要。试验注册:不相关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Danish medical bulletin
Danish medical bulletin 医学-医学:内科
自引率
0.00%
发文量
0
审稿时长
>12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信